Revenue Breakdown
Composition ()
No data
Revenue Streams
Novo Nordisk A/S (NVO) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Total GLP-1, accounting for 49.0% of total sales, equivalent to $5.75B. Other significant revenue streams include Obesity (Wegovy®) and Long-acting insulin. Understanding this composition is critical for investors evaluating how NVO navigates market cycles within the Pharmaceuticals industry.
Profitability & Margins
Evaluating the bottom line, Novo Nordisk A/S maintains a gross margin of 80.86%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 40.91%, while the net margin is 33.98%. These profitability ratios, combined with a Return on Equity (ROE) of 61.38%, provide a clear picture of how effectively NVO converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, NVO competes directly with industry leaders such as RDY and LLY. With a market capitalization of $168.60B, it holds a significant position in the sector. When comparing efficiency, NVO's gross margin of 80.86% stands against RDY's 53.63% and LLY's 82.52%. Such benchmarking helps identify whether Novo Nordisk A/S is trading at a premium or discount relative to its financial performance.
